Clinical Trials on Refractory Grade 2 Follicular Lymphoma

Total 1898 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
AIDS Malignancy Consortium
Center for International Blood and Marrow Transplant Research

Active, not recruiting

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (CS22-03)

HIV Infections | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Leukemia | Leukemia, Lymphoblastic | HIV Associated Lymphoma | HIV Disease; Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (GVHD)

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditions

United States
Centre Leon Berard

Terminated

BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) (BENEFIT)

Follicular Lymphoma

France
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
National Cancer Institute (NCI)

Completed

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
City of Hope Medical Center

Terminated

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Ruijin Hospital

Unknown

A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients

Lymphoma, Large B-Cell, Diffuse | Stage III Follicular Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Follicular Lymphoma and Marginal Zone Lymphoma

China
Duke University
Celgene

Terminated

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

United States
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
University of Miami

Terminated

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma

United States
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma and Marginal Zone Lymphoma

China
Hoffmann-La Roche

Completed

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Follicular Lymphoma

United Kingdom, Belgium, United States, Australia, Canada, Germany
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma | Chronic Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Mycosis Fungoides | Sezary Syndrome | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Primary Effusion Lymphoma | Adult T-Cell Leukemia/Lymphoma | Post-Transplant... and other conditions

United States
Shanghai Henlius Biotech

Withdrawn

Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

CD20-positive Follicular Lymphoma, With Low Tumour Burden
Gilead Sciences

Completed

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic | Leukemia, Prolymphocytic | NHL | CLL | Leukemia, Lymphocytic, Chronic | Lymphoma, Intermediate-Grade | Lymphoma, Large-Cell | Lymphoma, Mixed-Cell | Lymphoma, Small-Cell | Leukemia, B-Cell, Chronic | Leukemia... and other conditions

United States
Wake Forest University Health Sciences

Withdrawn

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
Centre Henri Becquerel

Completed

Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma (VAXIMAB)

Follicular Lymphoma | Mantle Cell Lymphoma

France
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma | Classic Follicular Lymphoma

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
Hoffmann-La Roche

Terminated

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma

United States, Australia, Germany, Korea, Republic of, New Zealand
Reid Merryman, MD
Genentech, Inc.

Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin Lymphoma

United States
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
AbbVie

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Israel
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
Austin Health
AstraZeneca; Olivia Newton-John Cancer Research Institute

Completed

A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD)

Follicular Lymphoma | Diffuse Large B Cell Lymphoma

Australia
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region (LymphoVi)

Follicular Lymphoma | Diffuse Large Cell Diffuse Lymphoma

France
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (REAL07)

Follicular Lymphoma | Non Hodgkin Lymphoma

Italy
Royal Marsden NHS Foundation Trust

Unknown

Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (BMPB)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
Stanford University
National Institutes of Health (NIH); Amgen

Completed

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Follicular Lymphoma | Acute Myeloid Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Mantle-Cell Lymphoma | Hematologic Malignancy | Small Lymphocytic Lymphoma | Burkitt's Lymphoma | Marginal Zone B-cell Lymphoma | Chronic Myeloproliferative... and other conditions

United States
Jonathan Friedberg
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (ILyAD)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Mucosal-Associated Lymphoid Tissue Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
BeiGene

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma

China

Clinical Trials on Refractory Grade 2 Follicular Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations